ArticleNature communications2022
Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.Human vaccines & immunotherapeutics · 2023Pooled it
- Inferring temporal trends of multiple pathogens, variants, subtypes or serotypes from routine surveillance data.American journal of epidemiology · 2025Article
- The importance of playing the long game when it comes to pandemic surveillance.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- From Emergence to Evolution: Dynamics of the SARS-CoV-2 Omicron Variant in Florida.Pathogens (Basel, Switzerland) · 2024Article
- Acute hepatitis of unknown aetiology in children: evidence for and against causal relationships with SARS-CoV-2, HAdv and AAV2.BMJ paediatrics open · 2024Review
- Challenges in the case-based surveillance of infectious diseases.Royal Society open science · 2024Article
- Article
- Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.Emerging infectious diseases · 2024Article
- Article
- Structural and genomic evolutionary dynamics of Omicron variant of SARS-CoV-2 circulating in Madhya Pradesh, India.Frontiers in medicine · 2024Article
- SARS-CoV-2 anti-N antibodies among healthcare personnel without previous known COVID-19.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Article
- Enhancing global preparedness during an ongoing pandemic from partial and noisy data.PNAS nexus · 2023Article
- Design and Implementation of a National SARS-CoV-2 Monitoring Program in England: REACT-1 Study.American journal of public health · 2023Article
- Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England.PLoS biology · 2023Article
- Comparative epidemic expansion of SARS-CoV-2 variants Delta and Omicron in the Brazilian State of Amazonas.Nature communications · 2023Article
- BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.PLoS pathogens · 2023Article
- Fractal-fractional age-structure study of omicron SARS-CoV-2 variant transmission dynamics.Partial differential equations in applied mathematics : a spin-off of Applied Mathematics Letters · 2022Article
- Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The SARS-CoV-2 pandemic has been characterised by the regular emergence of genomic variants. With natural and vaccine-induced population immunity at high levels, evolutionary pressure favours variants better able to evade SARS-CoV-2 neutralising antibodies. The Omicron variant (first detected in November 2021) exhibited a high degree of immune evasion, leading to increased infection rates worldwide. However, estimates of the magnitude of this Omicron wave have often relied on routine testing data, which are prone to several biases. Using data from the REal-time Assessment of Community Transmission-1 (REACT-1) study, a series of cross-sectional surveys assessing prevalence of SARS-CoV-2 infection in England, we estimated the dynamics of England's Omicron wave (from 9 September 2021 to 1 March 2022). We estimate an initial peak in national Omicron prevalence of 6.89% (5.34%, 10.61%) during January 2022, followed by a resurgence in SARS-CoV-2 infections as the more transmissible Omicron sub-lineage, BA.2 replaced BA.1 and BA.1.1. Assuming the emergence of further distinct variants, intermittent epidemics of similar magnitudes may become the 'new normal'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.